CINECA IRIS Institutional Research Information System

SCAGLIOTTI, Giorgio Vittorio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.796
AS - Asia 19.319
EU - Europa 17.990
SA - Sud America 950
OC - Oceania 524
AF - Africa 453
Continente sconosciuto - Info sul continente non disponibili 60
Totale 63.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.579
CN - Cina 12.149
IT - Italia 3.847
GB - Regno Unito 1.850
DE - Germania 1.815
IE - Irlanda 1.731
JP - Giappone 1.393
FR - Francia 1.370
SE - Svezia 1.259
KR - Corea 996
ES - Italia 925
IN - India 832
UA - Ucraina 794
CA - Canada 783
FI - Finlandia 702
TW - Taiwan 676
PL - Polonia 665
TR - Turchia 593
AT - Austria 572
VN - Vietnam 563
HK - Hong Kong 536
AU - Australia 460
NL - Olanda 443
BR - Brasile 431
MX - Messico 335
BE - Belgio 276
SG - Singapore 258
CH - Svizzera 243
GR - Grecia 239
DK - Danimarca 217
ID - Indonesia 195
RU - Federazione Russa 183
TH - Thailandia 175
PT - Portogallo 173
IR - Iran 170
RO - Romania 142
CO - Colombia 122
CL - Cile 118
EG - Egitto 113
IL - Israele 110
AR - Argentina 109
MY - Malesia 107
PE - Perù 96
NO - Norvegia 90
PH - Filippine 88
PK - Pakistan 84
ZA - Sudafrica 81
SA - Arabia Saudita 73
HU - Ungheria 65
NZ - Nuova Zelanda 64
CZ - Repubblica Ceca 56
HR - Croazia 55
RS - Serbia 55
MA - Marocco 53
EC - Ecuador 47
LB - Libano 44
EU - Europa 43
SI - Slovenia 41
NG - Nigeria 37
JO - Giordania 32
MO - Macao, regione amministrativa speciale della Cina 31
IQ - Iraq 30
SN - Senegal 28
BD - Bangladesh 27
SK - Slovacchia (Repubblica Slovacca) 26
TN - Tunisia 26
LT - Lituania 24
BA - Bosnia-Erzegovina 23
DZ - Algeria 23
EE - Estonia 22
PS - Palestinian Territory 20
BG - Bulgaria 19
AE - Emirati Arabi Uniti 17
CR - Costa Rica 17
PR - Porto Rico 17
SY - Repubblica araba siriana 17
AP - ???statistics.table.value.countryCode.AP??? 16
ET - Etiopia 16
KE - Kenya 16
LY - Libia 16
MK - Macedonia 15
BY - Bielorussia 14
KZ - Kazakistan 14
UZ - Uzbekistan 14
CY - Cipro 13
GT - Guatemala 12
GE - Georgia 10
LK - Sri Lanka 9
LV - Lettonia 9
QA - Qatar 9
VE - Venezuela 9
CU - Cuba 8
GH - Ghana 8
KG - Kirghizistan 8
NI - Nicaragua 8
RE - Reunion 8
AL - Albania 7
DO - Repubblica Dominicana 7
IS - Islanda 7
UY - Uruguay 7
Totale 62.980
Salva come PNG Salva come JPEG
Città #
Beijing 2.632
Chandler 1.720
Dublin 1.680
Houston 1.372
Fairfield 1.360
Shanghai 1.197
Redwood City 1.068
Ashburn 902
Torino 868
Wilmington 844
Woodbridge 726
Ann Arbor 707
Guangzhou 692
Nanjing 636
Seattle 632
Pisa 564
Cambridge 520
Medford 517
Jacksonville 499
Princeton 494
Vienna 488
Villeurbanne 446
Taipei 440
Warsaw 406
Tokyo 387
Nyköping 383
Dearborn 365
Chengdu 350
Hangzhou 343
Zhengzhou 302
Wuhan 299
New York 277
Dong Ket 275
Fremont 274
Changsha 258
Jinan 257
London 244
Turin 230
Shenyang 223
Boston 214
Milan 212
Buffalo 191
Duncan 182
Düsseldorf 171
Seoul 155
Hefei 152
San Diego 146
Nanchang 145
Toronto 139
Los Angeles 137
Istanbul 135
Tianjin 133
Madrid 131
Boardman 129
Central 128
Chongqing 124
Kunming 124
Central District 119
Harbin 119
Osaka 117
Singapore 115
Fuzhou 113
Ottawa 112
Changchun 111
Chicago 111
Xian 111
Barcelona 98
Hebei 96
Rome 93
Paris 92
Norwalk 86
Jakarta 78
Brussels 77
Athens 75
Lima 73
Verona 73
Munich 72
Santiago 70
Sydney 68
Ankara 67
Helsinki 65
Manchester 65
Bangkok 61
Falls Church 61
Suzhou 61
Guiyang 59
Seongnam 58
Chennai 57
Philadelphia 57
Hanoi 56
Lanzhou 56
Nanning 56
Washington 55
Amsterdam 54
Dallas 52
Delhi 52
Buenos Aires 51
Hyderabad 51
Phoenix 50
Polska 50
Totale 31.898
Salva come PNG Salva come JPEG
Nome #
Lung cancer: current therapies and new targeted treatments 15.377
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer 2.578
A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer 1.258
Papillary renal cell carcinoma: A review of the current therapeutic landscape 1.241
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s 1.216
Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis 1.150
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. 1.130
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer 1.116
Addressing the unmet need in lung cancer: The potential of immuno-oncology 1.001
Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer 782
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2 749
Novel anti-angiogenic therapeutic strategies in colorectal cancer 721
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? 641
Hormonal treatment and quality of life of prostate cancer patients: new evidences 625
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain 584
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. 582
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. 563
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer 480
Extending survival of stage IV non-small cell lung cancer. 479
Enzalutamide in metastatic prostate cancer before chemotherapy. 473
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer 461
Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled lume-meso trial 456
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 451
Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit 435
Apalutamide treatment and metastasis-free survival in prostate cancer 435
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1 372
Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. 351
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer 326
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC 323
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma non-small cell lung cancer. 317
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 313
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer 306
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations 282
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations 280
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome 263
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 256
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report 252
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis 250
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. 244
First-line crizotinib versus chemotherapy in ALK-positive lung cancer 241
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 238
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker 227
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 224
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 218
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 207
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy 206
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 199
Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC 197
The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. 190
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. 188
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: A case report and review of the literature 188
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era 188
Differentiation-inducing factor 1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and Thymidylate Synthase mRNAs accumulation 186
ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 186
Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study 182
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines 182
Systemic recurrence of endometrial cancer more than 10 years after hysterectomy: a report of two cases and a brief review of the literature 181
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 181
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 171
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 167
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 165
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 160
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 159
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy 158
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 153
Novel investigational therapies for treating biliary tract carcinoma 149
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018 149
Pros-IT CNR: an Italian prostate cancer monitoring project 146
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 144
Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. 141
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme. 141
The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study. 141
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers 140
Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. 132
International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma 128
Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer 128
Current state-of-the-art therapy for advanced squamous cell lung cancer 127
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. 127
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer 126
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 126
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 126
141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials 126
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 126
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis 126
Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. 122
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data 121
Thymidylate synthase expression in large cell carcinoma ofthe lung 120
Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. 115
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 108
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 106
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer: A Phase-II Study. 106
First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era 106
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung 105
Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions 104
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine 104
Enzalutamide-resistant castration-resistant prostate cancer: Challenges and solutions 104
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung 103
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 102
Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2 101
Diagnostica per immagini 99
Totale 48.336
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.587
article - articoli 0
book - libri 0
conference - conferenze 3.353
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.940
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.796 0 0 0 0 0 0 0 0 0 716 1.397 683
2019/202010.129 584 616 613 1.123 731 1.088 960 925 1.016 816 887 770
2020/202111.841 761 814 820 1.047 1.296 1.132 1.075 761 1.130 1.045 748 1.212
2021/20229.079 739 690 712 764 715 544 671 597 605 598 1.272 1.172
2022/20239.633 837 711 340 744 767 1.894 823 719 955 525 673 645
2023/20247.141 901 934 614 744 770 862 669 917 283 447 0 0
Totale 65.417